ABSTRACT
Background 1346 General description 1346 Clinical features 1347 ALK-positive and ALK-negative anaplastic large 1347
cell lymphoma Outcome 1347 Prognostic factors 1347
Primary cutaneous anaplastic large cell lymphoma 1348 Management 1348 Systemic anaplastic large cell lymphoma 1348 Cutaneous anaplastic large cell lymphoma 1349 Targeted therapies 1349 Key points 1350 References 1350
Anaplastic large cell lymphoma (ALCL) was first described 20 years ago as a novel entity characterized by a cohesive growth pattern of neoplastic lymphoid cells with anaplastic features and constant expression of the Ki-1/CD30 antigen.1
